Nyxoah’s Surge Hinges on 25% Sequential Growth—Can It Sustain the Burn?

The setup is perfect: FDA approval in August 2025 cleared the runway, and the first full quarter of U.S. sales delivered a 348% year-over-year revenue jump to €5.6M. That's explosive alpha. But the signal is mixed. While management guides for another ~25% sequential growth in Q1 2026, the path to profitability is paved with high burn. The company's cash position of €48.0M is a runway, not a cushion. This is a pure growth story where execution risk and capital intensity are the real red flags. Watch the surgeon training pace and reimbursement rates closely.

The Setup: FDA Approval Meets First Full Sales Quarter

The catalyst was clear. In August 2025, the FDA gave Nyxoah the green light, approving the Genio system for treating obstructive sleep apnea. That single event cleared the path for a full U.S. commercial launch. The company's execution in the following quarter was explosive. Q4 2025 wasn't just a start-it was a statement. For the first full quarter of U.S. sales, net revenue surged to €5.6 million, a staggering 348% year-over-year jump.

This wasn't a one-off. The momentum carried through the year. Full-year 2025 revenue hit €10.0 million, up 122% from the prior year. The setup was textbook: a major regulatory approval followed by immediate, massive commercial traction. Management didn't just report the numbers; they framed them as proof of a scalable model. They highlighted 145 surgeons trained and 57 U.S. accounts activated by year-end, plus a waiting list for more training, signaling strong demand from the medical community.

The alpha leak is real. But the real test is the path from this explosive start to sustainable growth. The company is guiding for another ~25% sequential net revenue growth in Q1 2026, which would keep the triple-digit growth narrative alive. The foundation is set. Now, the market watches to see if this initial surge can be maintained, or if it was simply the first wave of pent-up demand after a long approval wait.

The Breakdown: Growth Engine vs. Burn Rate

The numbers tell a clear story: the growth engine is firing on all cylinders, but the fuel tank is draining fast. Let's separate the top-line momentum from the bottom-line reality.

First, the good news on the product side. In Q4, the company achieved a gross margin of approximately 64%. That's a powerful signal. It means the core Genio system has strong pricing power and unit economics. Even with the initial operational ramp-up, the company is making a solid profit on each device sold. This is the kind of margin profile that investors love-it shows the business model can scale profitably.

The bad news is the massive investment required to ignite that engine. To launch in the U.S., Nyxoah had to build a commercial machine from the ground up. That's reflected in soaring expenses. For the full year, selling, general and administrative expenses surged to €48.3 million, up from €28.5 million in 2024. Combined with R&D, total operating losses ballooned to €83.5 million for 2025, a significant jump from €58.8 million the year before. This isn't a cost of doing business; it's the cost of a full-scale launch.

So where does that leave the cash? The company ended 2025 with a cash position of €48.0 million. That's a runway, not a cushion. Given the aggressive growth investments, that cash will burn at a high rate. The company is guiding for another ~25% sequential revenue growth in Q1 and Q2 of 2026. To hit those targets, it will need to keep spending heavily on sales, marketing, and training. The path to profitability is clear but long: you need to spend cash to grow, and you can only grow if you have cash to spend.

The bottom line is a classic high-growth, high-burn scenario. The strong gross margin proves the product works. The exploding SG&A proves the company is investing everything to capture the U.S. market. The watchlist now is simple: can the revenue growth outpace the burn rate before the cash runs dry? For now, the engine is loud and powerful, but the fuel gauge is flashing red.

Catalysts & Risks: What to Watch

The setup is clear. The first full quarter of U.S. sales was a blockbuster. Now, the market is waiting for proof that the commercial ramp can continue. The watchlist is simple, but the stakes are high.

The Watchlist: Sequential Growth or Bust The company's own guidance is the roadmap. Management expects ~25% sequential net revenue growth in Q1 2026 and another ~25% in Q2. Hitting those targets is non-negotiable. It validates the initial surge wasn't a one-time event and proves the launch strategy is scalable. Miss, and the entire growth narrative starts to crack. The consensus estimates for 2026 revenue are already rising, but the stock price is pricing in perfection. Any stumble in execution here will be punished.

The Contrarian Take: Pure Growth Bet, No Efficiency Play Let's cut through the hype. This isn't a story about operational efficiency or near-term profits. It's a pure, high-stakes growth bet on U.S. market penetration. The numbers are stark: a cash position of €48.0 million is the runway, not a war chest. The company is burning cash at a high rate to build its commercial machine. The strong gross margin of approximately 64% is the good news, but it's being completely offset by soaring SG&A. For now, the stock is a leveraged bet on the company's ability to train surgeons, activate accounts, and sell devices faster than it burns cash. If that growth stalls, the lack of profitability makes the downside severe.

The Risk: Execution is Everything The operational lift required is massive. In one quarter, the company trained 145 surgeons and activated 57 U.S. accounts. That's a monumental task for a new commercial organization. It's a high-risk, high-reward scenario. The risk isn't just missing revenue targets; it's the sheer complexity of scaling that fast. Any delay in surgeon training, reimbursement hurdles, or account activation could derail the sequential growth plan. This is execution risk at its peak. The company has built the engine, but can it keep it running at full throttle?

The bottom line is a binary setup. Hit the ~25% sequential growth targets, and the breakout story continues. Miss them, and the value trap becomes clear. The path is paved with high burn and high expectations. Watch the surgeon training pace and reimbursement rates like a hawk.